177 related articles for article (PubMed ID: 27525648)
41. Tumor necrosis factor-alpha induces insulin resistance in endothelial cells via a p38 mitogen-activated protein kinase-dependent pathway.
Li G; Barrett EJ; Barrett MO; Cao W; Liu Z
Endocrinology; 2007 Jul; 148(7):3356-63. PubMed ID: 17446186
[TBL] [Abstract][Full Text] [Related]
42. Melatonin improves glucose homeostasis and endothelial vascular function in high-fat diet-fed insulin-resistant mice.
Sartori C; Dessen P; Mathieu C; Monney A; Bloch J; Nicod P; Scherrer U; Duplain H
Endocrinology; 2009 Dec; 150(12):5311-7. PubMed ID: 19819971
[TBL] [Abstract][Full Text] [Related]
43. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
44. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism.
Liu L; Liu J; Wong WT; Tian XY; Lau CW; Wang YX; Xu G; Pu Y; Zhu Z; Xu A; Lam KS; Chen ZY; Ng CF; Yao X; Huang Y
Hypertension; 2012 Sep; 60(3):833-41. PubMed ID: 22868389
[TBL] [Abstract][Full Text] [Related]
45. Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects.
Kawakubo M; Tanaka M; Ochi K; Watanabe A; Saka-Tanaka M; Kanamori Y; Yoshioka N; Yamashita S; Goto M; Itoh M; Shirakawa I; Kanai S; Suzuki H; Sawada M; Ito A; Ishigami M; Fujishiro M; Arima H; Ogawa Y; Suganami T
Sci Rep; 2020 Jan; 10(1):983. PubMed ID: 31969650
[TBL] [Abstract][Full Text] [Related]
46. Acute glucosamine-induced insulin resistance in muscle in vivo is associated with impaired capillary recruitment.
Wallis MG; Smith ME; Kolka CM; Zhang L; Richards SM; Rattigan S; Clark MG
Diabetologia; 2005 Oct; 48(10):2131-9. PubMed ID: 16059714
[TBL] [Abstract][Full Text] [Related]
47. Synthetic (+)-antroquinonol exhibits dual actions against insulin resistance by triggering AMP kinase and inhibiting dipeptidyl peptidase IV activities.
Hsu CY; Sulake RS; Huang PK; Shih HY; Sie HW; Lai YK; Chen C; Weng CF
Br J Pharmacol; 2015 Jan; 172(1):38-49. PubMed ID: 24977411
[TBL] [Abstract][Full Text] [Related]
48. Dipeptidyl peptidase 4 inhibitor anagliptin ameliorates hypercholesterolemia in hypercholesterolemic mice through inhibition of intestinal cholesterol transport.
Goto M; Furuta S; Yamashita S; Hashimoto H; Yano W; Inoue N; Kato N; Kaku K
J Diabetes Investig; 2018 Nov; 9(6):1261-1269. PubMed ID: 29754453
[TBL] [Abstract][Full Text] [Related]
49. A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release.
Chu ZL; Carroll C; Alfonso J; Gutierrez V; He H; Lucman A; Pedraza M; Mondala H; Gao H; Bagnol D; Chen R; Jones RM; Behan DP; Leonard J
Endocrinology; 2008 May; 149(5):2038-47. PubMed ID: 18202141
[TBL] [Abstract][Full Text] [Related]
50. Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors.
Omar B; Ahrén B
Diabetes; 2014 Jul; 63(7):2196-202. PubMed ID: 24962916
[TBL] [Abstract][Full Text] [Related]
51. Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase.
Duplain H; Burcelin R; Sartori C; Cook S; Egli M; Lepori M; Vollenweider P; Pedrazzini T; Nicod P; Thorens B; Scherrer U
Circulation; 2001 Jul; 104(3):342-5. PubMed ID: 11457755
[TBL] [Abstract][Full Text] [Related]
52. The DPP-4 inhibitor linagliptin and the GLP-1 receptor agonist exendin-4 improve endothelium-dependent relaxation of rat mesenteric arteries in the presence of high glucose.
Salheen SM; Panchapakesan U; Pollock CA; Woodman OL
Pharmacol Res; 2015 Apr; 94():26-33. PubMed ID: 25697548
[TBL] [Abstract][Full Text] [Related]
53. Dipeptidyl peptidase-4 inhibitor, linagliptin, ameliorates endothelial dysfunction and atherogenesis in normoglycemic apolipoprotein-E deficient mice.
Salim HM; Fukuda D; Higashikuni Y; Tanaka K; Hirata Y; Yagi S; Soeki T; Shimabukuro M; Sata M
Vascul Pharmacol; 2016 Apr; 79():16-23. PubMed ID: 26277250
[TBL] [Abstract][Full Text] [Related]
54. Anagliptin inhibits neointimal hyperplasia after balloon injury via endothelial cell-specific modulation of SOD-1/RhoA/JNK signaling in the arterial wall.
Li Q; Zhang M; Xuan L; Liu Y; Chen C
Free Radic Biol Med; 2018 Jun; 121():105-116. PubMed ID: 29715547
[TBL] [Abstract][Full Text] [Related]
55. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice.
Shiuchi T; Iwai M; Li HS; Wu L; Min LJ; Li JM; Okumura M; Cui TX; Horiuchi M
Hypertension; 2004 May; 43(5):1003-10. PubMed ID: 15037562
[TBL] [Abstract][Full Text] [Related]
56. Enhancing effects of anagliptin on myoblast differentiation and the expression of mitochondrial biogenetic factors in C2C12 mouse skeletal muscle cells.
Han SE; Kim SJ; Kim YI; Nam-Goong IS; Jung HW; Kim ES
Clin Exp Pharmacol Physiol; 2020 May; 47(5):903-906. PubMed ID: 31943324
[TBL] [Abstract][Full Text] [Related]
57. Anagliptin suppresses diet-induced obesity through enhancing leptin sensitivity and ameliorating hyperphagia in high-fat high-sucrose diet fed mice.
Kohno D; Furusawa K; Kitamura T
Endocr J; 2020 May; 67(5):523-529. PubMed ID: 32009061
[TBL] [Abstract][Full Text] [Related]
58. Characteristics of GLP-1 and exendins action upon glucose transport and metabolism in type 2 diabetic rat skeletal muscle.
Arnés L; González N; Tornero-Esteban P; Sancho V; Acitores A; Valverde I; Delgado E; Villanueva-Peñacarrillo ML
Int J Mol Med; 2008 Jul; 22(1):127-32. PubMed ID: 18575785
[TBL] [Abstract][Full Text] [Related]
59. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline.
Gault VA; Lennox R; Flatt PR
Diabetes Obes Metab; 2015 Apr; 17(4):403-13. PubMed ID: 25580570
[TBL] [Abstract][Full Text] [Related]
60. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.
Matsubara J; Sugiyama S; Sugamura K; Nakamura T; Fujiwara Y; Akiyama E; Kurokawa H; Nozaki T; Ohba K; Konishi M; Maeda H; Izumiya Y; Kaikita K; Sumida H; Jinnouchi H; Matsui K; Kim-Mitsuyama S; Takeya M; Ogawa H
J Am Coll Cardiol; 2012 Jan; 59(3):265-76. PubMed ID: 22240132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
